In pre-clinical AML models, blocking CTLA-4 in combination with a peptide-based vaccine led to enhanced CTL responses and prolonged survival, providing rationale for targeting this receptor in AML patients. This evidence concerns the gene CTLA4 and acute myeloid leukemia.